Company / R&D Expense
Haemonetics R&D Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$62.7M
FY2024
5-year range
$46.8M / $62.7M
FY2020-FY2024
Trend
+15.2%
vs FY2023
Sector context
#72 of 105
Health Care
What the data says
At $63M, Haemonetics's r&d expense ranks #72 of 105 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $31M in FY2019 to $63M in FY2024.
Based on SEC 10-K filings.
$63M in FY2024 with a 5-year CAGR of +15.2%.
Improved from $50M to $63M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +10.3%
- 5-Year CAGR
- +15.2%
- 10-Year CAGR
- -
Sector benchmark
#72 of 105 in Health CareTop 69% of 105This company $62.7M Sector average $284.2M
▼
-77.9% below sector average
Key checks
Key Insights
- Haemonetics's r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +15.2%, indicating consistent growth.
- In FY2024, r&d expense increased 15.2% year-over-year.
- Ranks #72 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $62.7M | +15.2% |
| FY2023 | $54.4M | +8.6% |
| FY2022 | $50.1M | +7.1% |
| FY2021 | $46.8M | +42.4% |
| FY2020 | $32.9M | +6.4% |
| FY2019 | $30.9M | -13.5% |
| FY2018 | $35.7M | -9.0% |
| FY2017 | $39.2M | +4.5% |
| FY2016 | $37.6M | -16.5% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026